Answers are grounded in this paper and cite their sources.
Background Diabetic peripheral neuropathy (DPN) is most prevalent microvascular complication of diabetes; guideline-directed medications relieve pain in only a fraction of cases, and no recognized treatment reverses established DPN. The ancient Ayurvedisc texts describe Prameha and Madhumeha as a cluster of somatosensory manifestations and propose two therapeutic strategies: Panchakarma (cleansing practices) and Shamana (palliative medicine). Objective To perform critical description of the literature evaluating Ayurvedic interventions in patients with DPN, and to recognize evidence and safety gaps. Methods PubMed, MEDLINE, Scopus, the Cochrane Library, the AYUSH Research Portal, the DHARA (Digital Helpline for Ayurveda Research Articles) repository, and Google Scholar were interrogated up to 31 July 2026. This is a critical narrative review with single-author non-replicated screening. The working inclusion and exclusion criteria listed in Section 2 were applied retrospectively as a narrative-synthesis filter; the search was not pre-specified and the criteria were not finalized in advance of screening. The GRADE framework and an 8-domain rubric for case series are included as tools for reference only; no GRADE certainty assessment is reported, and the rubric is not a validated quality instrument. Key findings There is a preponderance of low-quality evidence from case reports and series, with multi-ingredient regimens precluding any individual treatment isolation. Basti (particularly Sahacharadi Yapana Basti and Panchatikta Ksheera Basti) and Shashtika Shali Pinda Sweda were the most frequently mentioned interventions, with symptomatic improvement reported in Diabetic Neuropathy Symptom Score and Toronto Clinical Scoring System in uncontrolled studies. Regarding isolated nanocurcumin, a 2019 RCT (n=80) was positive, whereas a 2025 RCT (n=97) found no significant effect. Safety information is limited: hypoglycemia during Langhana or Vamana is essentially undocumented, and Bhasma preparations have been associated with upper-limit concentrations of heavy metals (e.g., Pb 37,000 μg/g, Hg 104,000 μg/g). Conclusion Available evidence does not support the utilization of Ayurvedic interventions as surrogate treatments for guideline-directed DPN; they might inform hypothesis generation only, and Panchakarma therapies should be administered in specialized facilities within the supervision of endocrinology experts. There is need for appropriate Ayush-GCP-compliant clinical trials with rigorous blood-sugar monitoring, validated outcome measures, and predefined safety endpoints.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: